HUTCHMED (China) Limited (AIM:HCM)
198.50
-11.50 (-5.48%)
May 28, 2025, 4:35 PM GMT+1
HUTCHMED (China) Revenue
In the year 2024, HUTCHMED (China) had annual revenue of $630.20M USD, down -24.80%. HUTCHMED (China) had revenue of $324.52M in the half year ending December 31, 2024, with 44.64% growth.
Revenue
$630.20M
Revenue Growth
-24.80%
P/S Ratio
3.57
Revenue / Employee
$347.99K
Employees
1,811
Market Cap
1.80B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 630.20M | -207.80M | -24.80% |
Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
Dec 31, 2020 | 227.98M | 23.09M | 11.27% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
Genus | 671.60M |
Oxford Nanopore Technologies | 183.19M |
HUTCHMED (China) News
- 5 days ago - HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 7 days ago - AstraZeneca's record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer - Benzinga
- 4 weeks ago - HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025 - GlobeNewsWire
- 5 weeks ago - AIM Market Roundup: Catenai, Seeen, Hutchmed - The Armchair Trader
- 5 weeks ago - HUTCHMED Completes Enrollment for Phase II Trial of Savolitinib in Gastric Cancer | HCM stock news - GuruFocus
- 5 weeks ago - HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China - GlobeNewsWire
- 6 weeks ago - Hutchmed weighs cancer drug’s supply-chain options amid US-China trade war - South China Morning Post
- 2 months ago - HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma - GlobeNewsWire